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Genomic integrity is maintained by a network of cellular activities that assess the status of the genome at a 
given point in time, provide signals to proceed with or halt cell cycle progression, and provide for repair of 
damaged DNA. Mutations in any part of these pathways can have the ultimate effect of disturbing 
chromosomal integrity. Recent work suggests that p53 performs this integrator function in mammalian cells. 
Our present study demonstrates that in mortal cells, the expression of £6 and £7 viral oncoproteins of type 16 
human papillomavirus each disrupts the integration of these signals by diverged pathways. Cells expressing £6 
protein, which binds and degrades the p53 protein, exhibited alterations in cell cycle control when placed in 
drug and displayed the ability to amplify the CAD gene. The expression of £7, which binds different cellular 
proteins important for transformation, including Rb, led to a p53-independent alteration in cell cycle control, 
a widespread cytocidal response, and polyploidy as a mechanism of drug resistance. These results demonstrate 
that diverse perturbations of molecular pathways can have different effects on chromosomal integrity. 
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Loss of genomic integrity is a hallmark of neoplastic 
cells and fuels the multistep process of carcinogenesis. 
Changes in genomic integrity are seen when cells are 
transformed spontaneously, virally, or with chemicals. 
In studying the loss of genomic integrity, our previous 
work has focused on spontaneously transformed cells 
(both rodent and human) and their ability to exhibit one 
form of genetic instability, gene amplification. Gene am­
plification is an increase in gene copy number of a given 
locus and occurs spontaneously at a high frequency 
(10~^-10~^) in preneoplastic and neoplastic cells (Sager 
et al. 1985; Otto et al. 1989; Tlsty et al. 1989; Jonczyk et 
al. 1993). In contrast, gene amplification is undetectable 
in normal cells (<10~') as measured by the ability to 
become resistant to the drug N-(phosphonoacetyl)-L-as-
partate (PALA) (Tlsty 1990; Wrigjit et al. 1990). Genetic 
analysis of this property indicates that the ability to am­
plify is a recessive genetic trait (Tlsty et al. 1992). These 
data suggest that normal cells have a gene, or set of 
genes, that suppresses amplification. In our search for 
possible candidate genes, the p53 gene emerged as an 
important modulator of gene amplification frequency as 
well as other genomic alterations. 
^Conesponding author. 
One method of maintaining genomic integrity in­
volves the action of cell cycle checkpoint genes, which 
integrate proper sensing of environmental signals and 
appropriate cellular responses. Data to support this idea 
come from several sources, most importantly, studies of 
genes in yeast that control cell cycle progression. Hart-
well (Hartwell and Weinert 1989) has demonstrated that 
some of these genes, called checkpoint genes, coordinate 
cell cycle progression with cellular signals and allow for 
the maintenance of chromosomal integrity. In mamma­
lian cells, the p53 protein is part of a pathway that allows 
cells to arrest their cell cycle progression when condi­
tions for growth are unfavorable, such as the presence of 
antimetabohtes (Livingstone et al. 1992; Yin et al. 1992). 
One consequence of this action is to prevent the emer­
gence of drug-resistant colonies (Livingstone et al. 1992; 
Yin et al. 1992). Studies by Kastan and co-workers im­
plicate p53 in a similar activity, the cellular response to 
7-radiation (Kastan et al. 1991; Kuerbitz et al. 1992). In 
this capacity it is suggested that p53 receives informa­
tion that DNA damage has occurred and mediates, 
through the possible action of GADD 45, growth arrest 
after DNA damage in normal cells. Hence, p53 exhibits 
several fimctions of a checkpoint gene in mammalian 
cells and appears to play a key role in maintaining geno­
mic integrity. Further studies demonstrated that some 
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human tumorigenic cells showed loss of genomic integ­
rity while containing two wild-type p53 alleles, suggest­
ing that alternate pathways or alternate regulation of p53 
can bypass the role of p53. Therefore, mutations in p53 
protein are not the sole determinant for the regulation of 
genomic integrity (Livingstone et al. 1992). 
Ideally, to investigate events that promote the aquisi-
tion of genomic instability, a model system that starts 
with a normal cell and disrupts genomic integrity at a 
defined point was needed. The DNA tumor viruses pro­
vided such a system. Our previous studies (Jonczyk et al. 
1993) demonstrate that virally transformed cells possess 
the ability to amplify. In this study we used the human 
papillomavirus (HPV) type 16 (HPV-16) to determine 
when, after expression of viral oncoproteins, the cells 
acquire the ability to amplify genes. The HPVs include 
numerous genotypes that induce benign genital warts or 
tumors of the epithelial or fibroepithelial components of 
skin or mucosa. Numerous clinical, epidemiological, 
and molecular evidence associates specific viral types 
with the formation of carcinomas of the genital and oral 
mucosa (zur Hansen 1991). Some HPV types such as 16, 
18, 31, 33, 39 are referred to as "high risk" because of 
their association with cervical carcinoma. Other types 
such as 6 and 11 associated with benign lesions are 
termed "low risk." 
Although frequently found in cervical carcinoma cells, 
the presence of a high risk HPV type is not sufficient to 
trigger malignant progression. The virus may be present 
with a long latency and only rarely does progression of 
genital lesions into carcinomas occur (zur Hansen 1991). 
Expression of two viral proteins, E6 and E7, is consis­
tently found in the majority of cervical carcinomas and 
derived cell lines (Schwarz et al. 1985; Smotkin and 
Wettstein 1986; Baker et al. 1987; Wilczynski et al. 
1988). Expression of these two viral proteins is sufficient 
to efficiently inmiortalize human keratinocytes and ex­
tend the normal life span of human fibroblasts (Hawley-
Nelson et al. 1989; Mimger et al. 1989a; Watanabe et al. 
1989; Dhanwada et al. 1992). The HPV-16 E6 gene prod­
uct binds and aids in the degradation of p53 (Scheffner et 
al. 1990; Wemess et al. 1990) while the E7 gene product 
binds a set of proteins that includes hypophosphorylated 
pRb, pl07, pl30, and cyclin A (Dyson et al. 1989, 1992; 
Davies et al. 1993; Tommasino et al. 1993). The mech­
anistic consequences of these protein couplings on the 
neoplastic process is imder intense investigation. 
In this study we examine amplification potential, 
chromosomal integrity, and cell cycle perturbations in 
normal human fibroblasts that have been infected with 
genes that code for high risk HPV-16 and low risk HPV-6 
viral oncoproteins. We found that normal human fibro­
blasts that expressed type 16 E6/E7 together or E6 alone 
acquired the ability to generate PALA-resistant colonies 
by CAD gene amplification immediately after viral in­
fection . In contrast, the majority of cells expressing the 
E7 protein alone imderwent a rapid cytocidal response 
when placed in drug, with rare PALA-resistant variants 
acquiring multiple copies of chromosome 2 (aneuploidy) 
as a mechanism of drug resistance. In each case, these 
virally altered cells have clearly acquired genetic insta­
bility prior to immortalization, as all of these cells even­
tually underwent cellular senescence. Normal human fi­
broblasts carrying type 6 low risk HPV proteins do not 
disrupt the genomic integrity of NHF. Our data suggest a 
physiological consequence of these interactions and 
their importance in viral carcinogenesis; both results re­
late to the maintenance of genomic integrity. 
Results 
Geneiation of HPV-16 oncoprotein-infected NHF 
Introduction of the viral oncoproteins from HPV-16 into 
normal human fibroblasts (Materials and methods) was 
accomplished by use of a recombinant retroviral system. 
Retroviral constructs contained the gene coding for neo­
mycin resistance alone, or in combination with the open 
reading frames (ORFs) for HPV-16 E6/E7 together, or 
each of the viral oncoproteins individually (Fig. 1). Nor­
mal human fibroblasts at population doubling (PDL) 33 
(neo, E6) and PDL 36 (E6/E7, E7) were infected at high 
titer with the described retroviral vectors and selected in 
the neomycin analog G418 sulfate. Similar mmibers of 
G418 sulfate-resistant colonies arose from each retrovi­
ral infection. Resistant cells were pooled, resulting in the 
cell populations NHF neo, NHF16 E6/E7, NHF16 E6, 
and NHF16 E7. Radioimmimoprecipitation of HPV-16 
E6 and E7 proteins in the cell populations demonstrated 
their expression, with the E6/E7-infected population ex­
pressing both viral oncoproteins and the E6 and E7-in-
fected populations expressing the appropriate individual 
proteins (data not shown; Materials and methods; Hal-
bert et al. 1991). Analysis of p53 and pRB protein by 
Western blot revealed decreased p53 protein levels in 
E6-expressing cells and decreased pRb levels in E7-ex-
pressing cells (data not shown). Oncogene-expressing 
cells were examined for the effect of the viral proteins on 
genomic integrity and the cellular potential to amplify. 




Figure 1. Recombinant retroviral vectors containing HPV-16 
sequences. Expression of the HPV oncoproteins in NHF was 
accomplished by infection of the cells with retroviral vectors. 
The viral particles contained Moloney murine leukemia virus 
promoter-enhancer sequences (LTR, sohd box), HPV-16 E6/E7 
sequences together or separately (E6, stippled box; E7, horizon­
tally striped box), and under control of the SV40 promoter, the 
neomycin resistance gene (Neo, hatched box). Integration of the 
viral sequences into the NHF genome allowed stable expression 
of HPV protein(s) and conferred resistance to the neomycin an­
alog G-418 sulfate in the infected cell and progeny cells. (Dia­
gram modified from Halbert et al. 1991). 
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Characterization of chromosome complements in HPV-
infected NHF 
Chromosome complements were examined in the unin­
fected and HPV-infected NHF cells (Table 1). The kary-
otypic stability of the five cell populations was examined 
during their extended propagation in culture, using sam­
ples taken 20 PDLs after the viral oncogene-expressing 
populations were selected as well as prior to their senes­
cence in culture. Normal diploid karyotypes were ob­
served in the parental NHF cells at both early passage 
and at late passage close to senescence. At early passage 
after infection with the indicated oncoprotein-coding 
genes, the NHF neo, NHF 16 E6, and NHF 16 E7 cells 
produced karyotypes that were indistinguishable from 
the parental NHF cells (Table 1). All three had a basic 
normal karyotype with no rearrangements or telomeric 
association. The karyotypes of the NHF 16 E6/E7 cells at 
early passage were foimd to have telomeric association 
in 8% of the cells and rearrangements in 6% of the cells. 
The telomeric association figures seen were simple, each 
consisting of two recognizable chromosomes attached at 
their telomeres with no noticeable loss or gain of chro­
matin at the junctions. When the karyotypes of the E6/ 
E7- and E6-expressing cells were examined late in pas­
sage, they were found to have numerous genomic rear­
rangements. Few of the cells were diploid, and most 
contained multiple rearrangements, telomeric associa­
tions, and gross aneuploidy (T. Tlsty, in prep.). In con­
trast to the E6-expressing cells, the karyotypes of the 
E7-expressing cells at late passage were completely dip­
loid. 
Characterization of growth control in HPV-
infected NHF 
Cell morphology, PDL time, mortality, and behavior at 
confluence were examined in the uninfected and HPV-
16-infected NHF cells (Table 2). Morphologically, the 
HPV protein-expressing cells were indistinguishable 
from each other. Although similar to the uninfected 
NHF, all three of the HPV-infected cell populations were 
smaller and less extended than the NHF parental cells 
(Fig. 2). The PDL time of each cell population was deter­
mined. The parental NHF and NHF neo-containing cells 
had similar PDL times when grown in standard media. 
The NHF cells that expressed both viral oncoproteins 
demonstrated a slightly longer doubling time (Table 2). 
Past studies have indicated that individually, the E6 or 
E7 proteins of HPV-16 do not significantly influence the 
life span nor immortalize NHF, but together, the pro­
teins can efficiently extend the life span of NHF com­
pared with that of normal controls (Watanabe et al. 
1989). In agreement with these studies, we found the E6-
and E7-expressing cells senesced between 78 and 88 
PDL, whereas in the E6/E7-expressing cells an extension 
of life span of ~20 PDL compared with NHF was noted 
(Table 2). Immortalization of HPV oncoprotein-express-
ing fibroblasts is rare or negligible (Shay et al. 1993) and 
was not observed in this set of experiments. 
The oncoprotein-expressing cells demonstrated rather 
striking responses to growth conditions at confluence. 
As normal diploid fibroblasts such as NHF become con­
fluent, they become tightly packed in a monolayer and 
cease proliferation. This contact inhibition results in a 
cessation of progression through the cell cycle with the 
cells arrested in a GQ state indefinitely. The cells con­
taining E6/E7 together or E6 alone demonstrated a re­
sponse that was similar to each other but slightly differ­
ent than that exhibited by parental NHF. The cells 
formed a monolayer, and for the most part, arrested in 
growth, but infrequent mitotic figures could be observed 
even several days after the cells achieved confluence (Fig. 
2D,F). The cells could be held in this state for long peri­
ods of time (months). Interestingly, the E7-expressing 
cells demonstrated an entirely different response after 
Table 1. Karyotypic chaiacterization of NHF and HPV protein-expiessing fibroblasts 
Cell population 
Early passage populations 
NHF 
NHF neo (pd 40) 
NHF16 E6/E7 (pd 46) 
NHF16 E6 (pd 56) 
NHF16 E7 (pd 50) 
PALA-resistant subclones 
NHF16 E6/E7 CI 
NHF16 E6/ E7 C3 
NHF16 E6 CI 
NHF16 E6 C4 
Diploid^ 





















































A minimmn of 50 metaphase spreads was examined from each cell population. The numbers indicate the percentage of cells in each 
category. 
"Infrequently, in normal cells there is a random loss of a single chromosome or the observation of a tetraploid cell. These deviations 
are found in < 10% of normal cells. Our observations are in keeping with those reported for normal human fibroblasts and lymphocytes 
in the literature (Aurias 1993). 
^Telomeric association is defined as end-to-end fusion of chromosomes. 
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Table 2. Growth pioperties and frequency of PALA resistance 
*(PDL) Population doubling. 
(̂PE) Plating efficiency. 
•̂ (LDgo) Concentration of PALA that permits 50% survival. 






NHF 16 E7 
PDL^ 
time (hr) 
20 ± 0.52 
22 ± 2.9 
26 ± 3.2 
19 ± 1.4 










33 ± 0.05 
30 ±0.18 





13 ± 1 
12 ± 1 
19 ± 9 
24 ± 4 
11 ± 3 
PALA 







frequency (9 x LD50) 
(<1 X 10"^ 
(<1 X 10"^ 
3.8 X 10~^±2.7 X 107^ 
1.8 X 10-^ ±2.3 X 10-^ 
4.3 X 10-^ ±2.6 X 10-^ 
reaching confluence; they died (Fig. 2H). The cells 
formed a tight monolayer as they approached conflu­
ence, and mitotics could be detected, similar to those 
seen with the E6-expressing cells. However, after ~3 
days at confluence these cells first became thin, elon­
gated, and eventually roimded and refractile as they 
lifted from the plate and died, as measured by trypan 
blue uptake. Within 48 hr the plate was completely clear 
of adherent cells. 
Cellular response to metabolic inhibitor 
To analyze amplification potential in these cells, we in­
cubated them in the drug PALA under the standard con­
ditions of the clonogenic assay (see Materials and meth­
ods). The normal human fibroblasts and those expressing 
the viral oncoproteins demonstrated dramatic differ­
ences in both the cellular response to the drug and the 
generation of PALA-resistant colonies. Uninfected NHF 
cells and neo-containing NHF exhibited a response to 
PALA that we have found is typical of normal human 
fibroblasts. The cells remained on the plate and failed to 
increase their cell number. There was no observable out­
growth of PALA-resistant colonies. Hence, uninfected 
NHF cells, as described previously (Tlsty 1990; Wright et 
al. 1990; Livingstone et al. 1992), and those containing 
the neo control lacked a detectable frequency of CAD 
gene amplification. When E6/E7- and E6-expressing cells 
were incubated in PALA, the vast majority gradually en­
larged and sloughed from the plate over a period of 1-2 
weeks, resulting in clearing of cells from the back­
ground, hifrequent, nondividing cells remained in the 
background while actively growing PALA-resistant col­
onies emerged during the selection process. Those cell 
populations containing the E6/E7 proteins together or 
the E6 protein alone generated PALA-resistant colonies 
at a frequency of3.8xl0~^ and 1.8x10""^ respectively 
(Table 2; Fig. 3). 
In contrast, when E7-expressing cells were incubated 
in the presence of PALA, there was a distinctly different 
response to the drug, which resulted in the clearing of 
cells from the plate within ~6 days. The E7-expressing 
cells became thin, elongated, and refractile, and after 3 
days in PALA they began demonstrating a condensed, 
rounded morphology as they loosened from the substrate 
of the tissue culture plate. This morphological change is 
identical to that seen when these cells are held at con­
fluence and is reminiscent of an apoptotic sequence of 
events that is initiated in certain cells imder adverse con­
ditions. The characteristic nuclear degradation ladder 
that occurs during apoptosis was not detected by gel 
electrophoresis (data not shown). At the termination of 
the PALA selection with the E7-expressing cells (~6 
weeks later), there was no background of nondividing 
cells. The plate was cleared of cells except for the rare 
PALA-resistant colonies. Cells that expressed E7 alone 
generated PALA-resistant colonies at a frequency that 
was 10-fold lower than that observed for the E6/E7-ex-
pressing cells (Fig. 3). The frequencies of the generation 
of PALA-resistant colonies obtained with the viral onco-
protein-expressing cells are within the range of those ob­
served previously in preneoplastic and neoplastic cell 
lines (10-^ to 10"^) (Sager et al. 1985; Otto et al. 1989; 
Tlsty et al. 1989; Jonczyk et al. 1993). 
Whereas the drug resistance curves for the three HPV-
16-expressing cell populations revealed similar frequen­
cies of generation of PALA-resistant colonies (Fig. 3), 
there were differences in the amount of time required for 
the formation of the visible colonies. The average time 
for isolation of NHF-16 E6/E7 PALA-resistant subclones 
was 3 weeks, compared with 4 and 6 weeks for the E6 
and E7 PALA-resistant clones, respectively. The prolif­
erative capacity of isolated subclones also differed, pre­
dictably as a direct reflection of the effect the HPV pro­
teins on NHF life span in culture. The NHF 16 E6/E7 
PALA-resistant subclones grew very well. Ten E6/E7 
PALA-resistant clones were chosen for further study and 
were found to senesce at —86 PDL. PALA-resistant cells 
expressing only the E6 protein divided for fewer PDL 
than the subclones expressing both the viral oncopro­
teins. When expanded in culture they senesced at —PDL 
76. The NHF-16 E7 drug-resistant subclones had a dimin­
ished proliferative capacity when compared with the E6-
expressing subclones. The population ceased growth at 
—PDL 66. In the first set of experiments they ceased cell 
division before they could be expanded and examined for 
CAD gene copy number. We reinfected NHF cells at an 
earlier passage in subsequent experiments (passage 9) 
and were able to isolate PALA-resistant subclones for 
analysis of CAD gene copy number. These subclones 
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Figure 2. Morphology of normal and HPV-16 oncoprotein-ex-
pressing fibroblasts in the absence of PALA. Phase-contrast pho­
tographs of cells at subconfluence and confluence, grown in the 
absence of PALA, are shown. Cells were plated at 2x10^ cells 
per 60-cm petri dish and grown until they attained confluence. 
Cells were photographed at subconfluence after 3 days in cul­
ture and after 6 days at confluence. At subconfluence, the HPV 
protein-expressing cells were indistinguishable from each other 
[NHF16 E6/E7 (C); NHF16 E6 (£); NHF16 E7 (G)] but distinct 
from the control cell populations [NHF [A]-, NHFneo (not 
shown)]. NHF cells expressing the HPV proteins were smaller in 
size and had less extended processes compared with the parental 
cells. At confluence, control cell populations [NHF [B]-, NHFneo 
(not shown)] were a tight monolayer of nondividing, viable cells. 
In contrast, NHF cells expressing both the E6 and E7 proteins or 
only the E6 protein continued to proliferate after reaching con­
fluence as indicated by the presence of mitotic cells [NHF16E6/ 
E7 (D); NHF16E6 [F]]. Massive cell death occurred in the E7-
expressing NHF after 2-3 days at confluence. Death was verified 
by cellular incorporation of the dye trypan blue. Magnification, 
63X. 
ceased growth soon after isolation as w^ell. In summary, 
all PALA-resistant clones were mortal. 
As a control, NHF cells individually expressing low 
risk HPV-6 E6 and E7 proteins were assayed for PALA-
resistant colony formation. Studies of human cell trans­
formation have shown that HPV-6 does not efficiently 
immortalize primary, human epithelial cells (Schlegel et 
al. 1988; Pecoraro et al. 1989; Halbert et al. 1992). There 
is no evidence for cellular degradation of p53 by HPV-6 
E6 (Scheffner et al. 1990; Werness et al. 1990; Crook et 
al. 1991), and the affinity of HPV-6 E7 protein for cellular 
retinoblastoma protein (pRb) is ~ 10-fold lower than the 
affinity of HPV-16 E7 for pRb (Munger et al. 1989b; Bar-
bosa et al. 1990; Gage et al. 1990; data not shown). In the 
presence of PALA, the NHF expressing the HPV-6 E6 and 
E7 proteins exhibited a phenotype typical of uninfected 
normal human fibroblasts. The cells enlarged, remained 
on the plate, and failed to proliferate. There was no cy-
tocidal response nor PALA-resistant colony formation 
observed. These results suggested that the diminished 
ability of the type 6 viral proteins to efficiently bind 
specific cellular proteins (such as p53, pRb, etc.) when 
compared with the type 16 oncoproteins correlated with 
the lack of ability to generate drug-resistant variants at a 
detectable frequency. 
Mechanism of drug resistance 
Several PALA-resistant subclones from each of the viral 
oncogene-expressing cell populations were analyzed for 
amplification of the CAD gene. Fluorescent in situ hy­
bridization (FISH) analysis of the subclones verified in-
trachromosomal CAD gene amplification as the mecha­
nism of resistance to PALA in the E6/E7- and E6-ex-
pressing cells. In all cases, the amplified copies were 
clustered with no distinct patterns observable. Represen­
tative hybridizations are seen in Figure 4, A and B. Fur­
ther karyotypic analysis of two PALA-resistant sub­
clones from each of the cell populations indicated a va­
riety of chromosome rearrangements and telomeric 
CU 
0̂  
T ' 1 ' 1 ' 1 ' r 
0 2 4 6 8 10 
PALA Concentration (X LD50) 
Figure 3. Determination of PALA resistance. Cells were plated 
at appropriate densities and placed in PALA concentrations in­
dicated. When drug-resistant colony size exceeded 50 cells, col­
onies were fixed, stained, and counted. Relative plating effi­
ciency (RPE) is the ratio of the percentage of cells surviving in 
PALA to the percentage of cells surviving in the absence of 
PALA. PALA resistance frequency was determined by the RPE 
value at 9x LD50. The curves are an average of at least four 
determinations. {•) NHF-16 E6/E7; (D) NHF-16 E6; (■) NHF-16 
E7. 
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Figure 4. Fluorescence in situ hybridiza­
tion of HPV-16 protein-expressing PALA-
resistant clones. Metaphase spreads from 
PALA-resistant subclones NHF16 E6/E7, 
clone 120-1 {A], and NHF16 E6, clone 
180-4 {B], were hybridized to a human 
CAD gene probe to locate CAD gene se­
quences as described previously (Tlsty et 
al. 1992). The normal loci for the CAD 
gene is on chromosome 2. CAD gene am­
plification in the subclones was mani­
fested as multiple copies of the gene in 
tandem arrays on a single chromosome 
arm. The PALA-resistant NHF16 E7 cells 
ceased proliferation when subcloned. Met­
aphase spreads were not obtained. Instead, 
interphase cells were analyzed for CAD 
gene and chromosome 2 centromere se­
quence copy number using different col­
ored fluorochromes to determine whether 
the mode of drug resistance was gene am­
plification or multiple copies of chromo­
some 2. Equivalent CAD gene copies and 
centromere 2 sequences were observed in 
most clones, although in some clones cen­
tromere 2 sequences were more abundant 
than the CAD gene. Positive signals in the 
interphase cells are indicated by open ar­
rowheads. (C) NHF16 E7, clone 108-2D 
centromere 2; (D) CAD gene 
associations (Table 1), similar to that seen in the unse-
lected populations after extended passage in culture. 
Analysis of PALA-resistant subclones from the E/-ex­
pressing population v̂ âs difficult because of their limited 
proliferative capacity and the difficulty in obtaining ad­
equate metaphase spreads. Although complete karyo-
typic analysis was not possible, several samples were 
noted to have excessive numbers of chromosomes 
(<100). As an alternative to metaphase analysis, two-
color FISH analysis was performed on interphase prepa­
rations using probes specific for human chromosome 2 
centromeric sequences and for the human CAD gene. 
Most often, multiple copies of centromeric chromosome 
2 and of the CAD gene (four to seven copies) were de­
tected indicating chromosome 2 aneuploidy as the pri­
mary mechanism of resistance to PAL A (Fig. 4C,D). Hy­
bridization with sequences specific for chromosome 6 
also demonstrated multiple signals suggesting possible 
polyploidy (data not shown). 
Perturbed cell cycle progression 
Our previous studies had shown that normal human fi­
broblasts arrested in the G^ and G2 phases of the cell 
cycle when incubated with PAL A (Livingstone et al. 
1992). Figure 5, A-G, shows the cell cycle distribution of 
normal cells at various times after placement in drug (0, 
1, 2, 3, 4, 5, 6 days). Hours after exposure to the meta­
bolic inhibitor PALA, an exponentially growing popula­
tion of normal, diploid cells accumulated the majority of 
the cells in the S phase of the cell cycle. This increased 
S fraction gradually decreased until, at day 2, there is a 
complete absence of cells in the S phase indicating an 
arrest in cell cycle progression. The population was dis­
tributed between the Gj and G2 phases of the cell cycle 
for the duration of the selection. This temporal distribu­
tion of cells within each phase of the cell cycle is pre­
sented as a scatter plot (data directly from the flow cy-
tometer) in Figure 5, A-G, and as a compilation over 
time in Figure 5H. This graphic representation of the 
relative fractions of the population in G^, S, or G j /M 
phase is helpful for comparing the response of normal 
cells in drug with that of the oncoprotein-expressing 
cells in drug. The status of multiple checkpoint func­
tions can be monitored at one time. The white area on 
the graph in Figure 5H represents the percent of cells in 
the S-phase fraction, whereas the lower gray area repre­
sents those in Gi, and the upper dark area represents 
those in G2. 
Deviations from this pattern were seen in the NHF 
cells expressing HPV-16 viral oncoproteins. In this assay, 
the various cell populations are pulsed with BrdU prior 
to harvesting. Only the cells that are actively incorpo­
rating nucleotides for synthesis of DNA during that pe­
riod of time will appear in the S-phase fraction. Figure 6A 
demonstrates that after 2 days of incubation in PALA, 
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BrdU-FITC 
2 4 
Days in PALA 
Figure 5. Flow cytometric analysis of NHF cell population in PALA. Cells were labeled with BrdU, fixed, and stained with anti-
BrdU-FITC and propidium iodide, and analyzed using a Becton Dickinson FACScan instrument. The x-axis represents cells undergoing 
DNA synthesis. Cells at the right have more BrdU incorporated and are therefore in the S phase of the cell cycle. The y-axis represents 
DNA content as measured by propidium iodide staining. The upper population has a G2 phase DNA content, and the lower population 
has a Gi phase DNA content. {A) NHF with no PALA exposure; {B-G) NHF days 1-6 in PALA. The cell cycle data were compiled and 
presented in the form of an area graph, providing a characteristic cell cycle pattem that could be conveniently compared among the 
cells [H], Each graph indicates the percentage of cells in each phase of the cell cycle (ordinate) as a function of time (axiS; 0, 1, 2, 3, 
4, 5, and 6 days in PALA). The Gj, S, and Gj phases of the cell cycle are represented by the top, middle, and bottom areas of the graph, 
respectively. There was no significant portion of the parental NHF cells in S phase after 2 days in PALA. 
none of the control cells are entering or actively partic­
ipating in the S phase of the cell cycle. This is repre­
sented by a lack of white area in the graph beyond 2 days. 
In contrast, at a similar point in time, those cells ex­
pressing HPV-16 E6 and E7 demonstrate that a large frac­
tion of the cells are incorporating BrdU (Fig. 6B). These 
cells are distributed throughout the S-phase arc (seen in 
Fig. 5A) indicating that cells are actively synthesizing 
DNA days after the normal cells have ceased. Expression 
of the HPV-16 E6 or E7 individually (Figure 6C;D) also 
relieves checkpoint arrest but in reproducibly distinct 
patterns (compare S-phase fractions at day 2). Finally, 
analysis of cells expressing low risk HPV-6 proteins 
showed a complete arrest when the cells were incubated 
in PALA (Fig. 6E,F). These cells continue to respond to 
negative growth signals. 
Discussion 
In this study we demonstrated that distinct alterations 
in growth control circuitry can lead to different types of 
genomic instability. We began with cell populations that 
were isogenic and, by expression of HPV-16 E6 and E7 
oncoproteins, contained disruptions in specific circuits 
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Days inPALA 
Figure 6. Flow cytometric analysis of NHF retrovirus-infected 
cell populations in PALA. Cells were treated and data are dis­
played as in Fig. 5. There was no significant portion of cells in 
S phase after 2 days in PALA for cells expressing only the neo­
mycin resistance gene and cells expressing the nononcogenic 
HPV-6 E6 or HPV-6 E7 proteins. All of the HPV-16 protein-
expressing cells continue to cycle in the presence of PALA, as 
indicated by a percentage of cells in the S phase throughout 
PALA exposure. [A] NHF neo; (B) NHF16 E6/E7; (C) NHF16 E6; 
(D) NHF16 E7; (£) NHF6 E6; (F) NHF6 E7. 
that allowed cells to respond to altered growth condi­
tions. It is important to note that the differential re­
sponse of the cells depended on their need to respond to 
outside stimuli. The two stimuli described here are the 
negative growth signals that cells produced as they at­
tained confluence or when the media was deficient in 
nutrients (in this case, nucleotide precursors). In the ab­
sence of either of these signals, each of the cell popula­
tions grew in an exponential fashion with no overt dif­
ficulties. 
When exposed to the metabolic inhibitor PALA, nor­
mal human fibroblasts arrest in the G^ and G2 phases of 
the cell cycle. Each of the virally altered cell populations 
failed to arrest under these conditions and continued to 
cycle. While the majority of these cells died, a few gen­
erated drug-resistant colonies. In the cells where p53 
function was compromised, cells with E6/E7 or E6 pro­
tein only, the majority of cycling cells died gradually, 
leaving the PALA-resistant colonies to expand. The al­
tered karyotypes of these drug-resistant clones mani­
fested CAD gene amplification in addition to other ge­
nomic changes. Rare PALA-resistant colonies arising 
from a background of gradually dying cells is the typical 
observation in most of the immortalized and tumori-
genic cell lines that we have assayed to date. A plausible 
scenario begins to emerge as to how p53 participates in 
the generation of the rearrangements that fuel neoplasia. 
Cells suffer either endogenous or exogenous damage to 
their DNA, which brings about breakage of their genetic 
material. Broken chromosomes are usually detected in a 
normal cell, and cell cycle progression is arrested while 
the damage is repaired or the cell is removed. In cells 
that have mutated parts of the circuitry that sense, re­
pair, or respond to damage in DNA, cell cycle progres­
sion fails to arrest. Broken chromosomes can replicate 
and fuse leading to the formation of dicentric chromo­
somes (Trask and Hamlin 1989; Toledo et al. 1992). The 
formation of a dicentric chromosome and the subse­
quent fusion-bridge-breakage cycle originally described 
by McClintock >40 years ago (McClintock 1939, 1942), 
generates duplications, deletions, and other abnormali­
ties. These dicentric intermediates are seen quite often 
in cells with amplified genes (Smith et al. 1990; Windle 
et al. 1991; Toledo et al. 1992; Ma et al. 1993). These 
types of rearrangements activate oncogenes and inacti­
vate tumor suppressor genes. 
Whereas the elimination of checkpoint function of p53 
could have accounted for the tolerance of broken chro­
mosomes and the emergence of cells with amplified 
DNA sequences in the E6-expressing cells, the E7-ex-
pressing cells also generated PALA-resistant colonies. 
Here, the cellular and genomic response was totally dif­
ferent. The cells expressing only the E7 protein exhibited 
massive, immediate cell death after ~3 days in PALA, 
with very rare resistant colonies arising on a cleared 
background (2x10"^ to 6x10"^). These drug-resistant 
cells contained increased copies of CAD gene sequences, 
along with increased copies of chromosome 2 centro-
meric sequences, indicating that aneuploid cells had 
been generated. How expression of the E7 oncoproteins 
influences the formation of aneuploid cells is not known 
at the present time. A previous report indicated that 
HPV-16 E7 can induce cytogenetic abnormalities in im­
mortalized keratinocytes (Hashida and Yasumoto 1991). 
As demonstrated in Figure 6D, these cells failed to arrest 
in cell cycle progression when placed in PALA even 
though they contained a wild-type p53 gene. This p53-
independent abrogation of cellular arrest, in some man­
ner yet to be determined, leads to chromosomal conse­
quences that are clearly distinct from those generated in 
cells that have eliminated p53. One may speculate that 
E7, which is known to bind cyclin A as well as cellular 
kinases (Dyson et al. 1992; Davies et al. 1993; Tomma-
sino et al. 1993), disrupts cyclin homeostasis and leads to 
elimination of G2 or relaxation of G2/M checkpoints. 
Because aneuploidy is one of the most common genomic 
aberrations seen in tumor cells, this mechanism de­
serves further investigation. Studies with polyoma T an­
tigen indicate that the expression of this gene in NHF 
cells also produces drug-resistant colonies, but the spec­
trum of genomic changes differs from those seen with 
HPV-16 E6/E7 (Schaefer et al. 1993). These results dem­
onstrate that diverse perturbations of molecular path­
ways can have different effects on chromosomal archi­
tecture, and although there are functional similarities in 
some DNA tumor virus proteins (Vousden and Jat 1989; 
Wemess et al. 1990), there are also important differences 
among them. 
These experiments demonstrated that expression of 
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viral oncoproteins lead to the immediate acquisition of 
the ability to amplify the CAD gene sequences. These 
cells relinquished their control of genomic integrity 
prior to immortalization, clearly indicating that this 
change is not necessary. Because previous studies with 
Syrian hamster epithelial cells identified immortal cells 
that lack the ability to amplify (sup"^ cells) (Jonczyk et 
al. 1993); and this study documented mortal cells that 
have the ability to amplify, it is clear that immortaliza­
tion of mammalian cells is neither necessary nor suffi­
cient for amplification to occur. Our observation of am­
plification in these mortal cells also addressed our initial 
question as to when the virally infected cells acquired 
the ability to amplify or undergo genomic rearrange­
ments. This change must occur immediately with ex­
pression of the E6/E7 genes. 
Strikingly, the biology of cervical carcinomas points to 
the expression of E6 and E7 as important in tumor pro­
gression. The high risk viruses are episomal in benign 
lesions, and in this state, the product of the HPV E2 ORE 
generates a protein that suppresses transcription of the 
E6 and E7 genes. Little protein is made. In carcinomas, 
the high risk viruses are usually found integrated into 
the host genome (Durst et al. 1985; Pater and Pater 
1985). This integration event is accompanied by a change 
in transcriptional activity and pattern. Reproducibly, 
this integration results in the disruption of the coding 
region between the El and E2 genes and consequently 
allows for the more efficient expression of E6 and E7 
transcription and subsequent protein production (Ro-
manczuk and Howley 1992). Whereas in the episomal 
state, the entire spectrum of viral proteins that are used 
for replication, capsid formation, and so on, are ex­
pressed, in the integrated state, the E6 and E7 viral on­
cogenic products become the dominant transcripts. Our 
data demonstrate that expression of these oncoprotein 
products and their concomitant functional inactivation 
of cellular proteins results in genomic instability. The 
generation of chromosomal rearrangements ostensibly 
allows progression of the malignant state. 
In addition to mediating growth arrest, p53 is impli­
cated in another process that may serve to protect the 
organism from a defective genome, the triggering of ap-
optosis, an active deith process (Debbas and White 1993; 
Yonish-Rouach et al. 1993). Our observations with HPV-
16 E6/E7 expression in human cells parallel recent work 
with adenovirus El A/EIB in a striking manner, suggest­
ing further functional analogies between the various vi­
ral oncoproteins. The E6 and ElB oncoproteins are func­
tional homologs while the E7 and El A oncoproteins 
share DNA sequence and functional homology. Cells ex­
pressing El A alone show a rapid loss of viability imme­
diately upon achieving saturation density. Those cells 
expressing both El A and ElB do not demonstrate this 
rapid cytocidal response (Rao et al. 1992). Transforma­
tion of rodent cells by the adenovirus oncoproteins El A 
and ElB requires two events, ElA-dependent induction 
of proliferation and EIB-dependent suppression of apop-
tosis. The sole expression of El A results in efficient ini­
tiation of focus formation, but the cells cannot sustain 
proliferation. They degenerate and die. Cell death is me­
diated through an up-regulation of p53 that results in the 
production of a cytocidal and DNA degradation pheno-
type. If p53 is functionally removed from these cells, as 
when ElB is coexpressed, the apoptotic pathway can no 
longer be induced. The ElA/EIB-expressing cells can 
now produce transformed foci with a high frequency that 
have a good probability of immortalizing. In our system 
the sole expression of the E7 gene in challenged cells 
resulted in a cytocidal response and the formation of 
drug-resistant colonies that cannot sustain proliferation. 
If p53 is functionally removed from these cells, as when 
E6 is coexpressed, the cytocidal response is no longer 
induced and the drug-resistant colonies grow in a 
healthy manner. In each case, a negative growth signal 
(confluence in the rodent cells and nutrient deprivation 
or confluence in the human fibroblasts) elicited a phys­
iological response that is similar in each cell type and 
dependent on the genotype of the cell. 
Finally, the studies presented here may provide the 
biological basis for the differences between high risk and 
low risk HPV types in terms of neoplastic transforma­
tion. Both the high risk and low risk viruses cause hy-
perproliferation in cells, yet only the high risk viruses 
produce cellular variants that can escape differentiation, 
immortalize, and progress to malignancy (zur Hansen 
1991). The high risk viruses are known to be much more 
efficient in binding and degrading p53 than their low risk 
counterparts (Werness et al. 1990; Scheffner et al. 1990; 
Crook et al. 1991). Likewise, the high risk E7 protein 
binds pRB with a 10-fold greater affinity than the low 
risk type (Munger et al. 1989a). We propose that one of 
the basic differences between these two types of viruses 
is their maintenance of genomic integrity. Two pieces of 
data demonstrated that cells infected with low risk virus 
maintained their genomic integrity while those express­
ing the high risk virus did not. First, no PALA-resistant 
colonies were generated when cells infected with HPV-6 
E6 or E7 were challenged with drug. The frequency was 
at least two orders of magnitude lower than measured 
with HPV-16. Second, the cells expressing the low risk 
HPV-6 E6 anc E7 genes can arrest in cell cycle progres­
sion when exposed to PALA or confluence, demonstrat­
ing that these cells sense negative growth signals and 
respond in an appropriate manner; they arrest. In con­
trast, the biology of the cells containing the high risk 
virus pointed to the involvement of E6 and E7 in the loss 
of genomic integrity and in tumor progression. 
Materials and methods 
Cell populatons and culture conditions 
All cells were grown in a minimal essential medium minus 
nucleosides and deoxyribonucleosides, but containing glu-
tamine and 10% dialyzed fetal bovine serum (JRH Biosciences). 
Primary, human foreskin fibroblasts were obtained from Dr. M. 
Cordiero-Stone (University of North Carolina at Chapel Hill). 
At PDL 33 or 36, cells in log phase growth were infected with 
retroviral vectors containing only the neomycin resistance gene 
(vector LXSN), vectors containing the neomycin gene and HPV-
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16 ORFs for the E6 and/or E7 proteins (LXSN16E6E7, 
LXSN16E6, or LXSN16E7), or vectors containing the neomycin 
resistance sequences and HPV-6 E6 or E7 ORFs (LXSN6E6 and 
LXSN6E7). The vectors were a gift from Dr. Denise Galloway 
(Fred Hutchinson Cancer Center, Seattle, WA) and have been 
described previously (Halbert et al. 1991). 
Retroviral infections 
Retroviruses containing the various vectors were produced by 
the murine cell line PAS 17. The procedure for retroviral infec­
tion entailed the following. NHF cells were incubated for 8-10 
hr in filtered, polybrene-supplemented medium from the PAS 17 
cells containing the appropriate retrovirus. The NHF cells were 
trypsinized and seeded at varying densities in medium contain­
ing 500 mg/ml of G418 sulfate (Geneticin, GIBCO-BRL Labo­
ratories). G418-resistant colonies were visible in ~1 week and 
were pooled for each cell population. Cell populations were des­
ignated NHF neo, NHF16 E6/E7, NHF16 E6, NHF16 E7, NHF 
6E6, and NHF 6E7. 
PDL time determination 
PDL time for each cell population was determined by plating 
~5xlO'* cells in each of ten 100-mm petri dishes. Cell counts 
from two dishes were averaged daily, beginning 24 hr postplat-
ing, and plotted as a function of time. Total PDLs were deter­
mined by plating a known cell number and counting cells at 
each passage until senescence. 
Karyotypic analysis 
The procedure used to obtain G-banded chromosomes was de­
scribed previously (Livingstone et al. 1992). Each cell population 
was analyzed in the absence of PALA. PALA-resistant NHF 16 
E6E7 and NHF 16 E6 subclones were also analyzed. 
Clonogenic assay 
The assay is used to determine gene amplification frequency 
and has been described previously (Otto et al. 1989). Briefly, 
cells were grown in the presence of the drug PALA, which spe­
cifically inhibits the aspartate transcarbamylase activity of the 
multifunctional CAD enzyme involved in de novo pyrimidine 
synthesis. PALA selects for cells with CAD gene amplification. 
Cells were plated in 100-mm dishes at densities of 2x10-^ to 
2x10'* cells and in 150-mm dishes at densities of 2x10^ cells. 
PALA-resistant colonies of 50 cells or greater were detectable 
after 2-6 weeks and were fixed, stained, and counted. Plating 
efficiency, the ratio of the number of colonies obtained without 
PALA selection to the number of cells seeded (100% survival), 
and LD50, the concentration of PALA that allows 50% survival, 
were determined for each cell population so that direct compar­
isons among the cells could be made. Amplification frequency 
was expressed as the number of PALA-resistant colonies at 9 x 
LD50 relative to the plating efficiency of the cell population. 
PALA was obtained from the Drug Evaluation Branch of the 
National Cancer Institute. 
FISH 
PALA-resistant subclones (9x LD50 and above) were analyzed 
for CAD gene amplification by FISH as described previously 
(Tlsty et al. 1992). The human CAD probe was a kind gift from 
Dr. J. Davidson (University of Kentucky, Lexington). Probe for 
centromeric sequences of chromosome 2 was purchased from 
Oncor. 
Cell cycle analysis 
Cells were plated in regular growth medium or medium con­
taining PALA at 9 X LD50 for the respective cell strain. A mod­
ification of the cell cycle analysis used by Kastan and co-work­
ers was used (Kastan et al. 1991). On days 0-6, BrdU was added 
to a log phase population of cells at a concentration of 10 mM, 
and after 4-5 hr the cells were trypsinized and counted, and 
then fixed using 1.5 ml of cold phosphate-buffered saline and S 
ml of cold 95% EtOH per 10^ cells. The fixed cells were pro­
cessed as follows for propidium iodide staining. Two million 
fixed cells were centrifuged for 5 min at 1200 rpm using a Sor-
vall HTIOOOB rotor at 4°C, and the pellet was resuspended with 
vortexing in S ml of 0.08% pepsin. 7\fter a 20-min incubation at 
S7°C, the nuclei were centrifuged as above and resuspended in 
1.5 ml of 2N HCl while vortexing. After 20 min at S7°C, S ml of 
0.1 M sodium borate was added to neutralize the nuclei and they 
were centrifuged for 5 min. The pellet was resuspended in 2 ml 
of IFA (10 mM HEPES at pH 7.4, 150 mM NaCl, 4% serum, 0.1% 
sodium azide) with 0.5% Tween 20 and centrifuged as above. 
The nuclear pellet was resuspended in 100 JJLI of a 1:5 dilution of 
anti-BrdU fluorescein isothiocynate-conjugated antibody (Bee-
ton Dickinson) in IFA. After a SO-min incubation on ice in the 
dark, 2 ml of IFA with 0.5% Tween 20 was added and the tubes 
were centrifuged for 5 min. The nuclei were suspended in 500 -̂1 
of IFA, RNase A (Sigma) was added to 5 |xg/ml, propidium io­
dide (Aldrich Chemical Co.) was added to 50 |xg/ml, and incu­
bation proceeded at S7°C for 15 min. The nuclei were kept in 
the dark, on ice for at least 15 min. Cell cycle analysis was then 
performed using a Becton Dickinson FACScan instrument. 
Immunoprecipitation of viral and cellular proteins 
Cells (2x10^) were incubated in methionine and cysteine-free 
Dulbecco's modified Eagle medium (DMEM), for 1 hr at 37°C 
and were then labeled for 3 hr with 80 ixCi/ml of Tran^^S-label 
(70% L-['̂ ^S]methionine and L-[^^S]cysteine, ICN. Incubation in 
800 |xl of lysis buffer (20 mM Tris at pH 7.4, 250 mM NaCl, 0.5% 
NP-40, 1 mM EDTA, 50 M-g/ml of leupeptin, SO |xg/ml of apro-
tinin) for 10 min at 4°C was followed by centrifugation at 14,000 
rpm for 30 min to remove cellular debris. Lysates were pre-
cleared by absorption with Sansorbin (Calbiochem) for SO min 
on ice and microcentrifuged for 15 min. Equivalent trichloro­
acetic acid precipitable counts (5x10'') of radioactive protein 
were immunoprecipitated with protein A-Sepharose coated 
with mouse anti-HPV-18/16E6 (Oncogene Science), anti-HPV-
16E7 (Denise Galloway), anti-human p53 protein (p53 Ab-5, On-
cogence Science), or anti-retinoblastoma protein antibody (RB 
Ab-1, Oncogene Science) for 2 hr. Immune complexes were 
washed four times in wash buffer (20 mM Tris at pH 7.4, 150 mM 
NaCl, 0.5% NP-40, 0.1% SDS), twice in PBS, released from the 
beads by heating to 95°C, and separated on 12% SDS-polyacryl-
amide gels. Gels were fixed, treated with Amplify (Amersham), 
dried, and exposed to x-ray film. 
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